Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2024-05-22 00:00:00 ET · period of report 2024-05-20 · accession 0000875320-24-000156 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-05-22 | 2024-05-20 | VRTX | Kewalramani Reshma | CEO, Pres, Dir | S - Sale | $447.00 | -15.2K | 121.4K | -11% | -$6.80M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-05-20 | S | D | 15,202 | $447.00 | 121,374 | D | — | — |